Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic Optivate Treatment in Subjects with Severe Haemophilia A.
Phase of Trial: Phase IV
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Factor VIII/von Willebrand factor (Primary)
- Indications Haemophilia A
- Focus Pharmacodynamics
- Sponsors Bio Products Laboratory
- 12 Jul 2017 Planned End Date changed from 1 Jan 2018 to 1 Aug 2017.
- 12 Jul 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jul 2017.
- 12 Jul 2017 Status changed from recruiting to discontinued.